Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $30.7 million.

  • Amylyx Pharmaceuticals' Total Liabilities fell 4359.75% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 4359.75%. This contributed to the annual value of $28.9 million for FY2024, which is 6564.11% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Total Liabilities stood at $30.7 million for Q3 2025, which was down 4359.75% from $26.7 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Total Liabilities' 5-year high stood at $93.0 million during Q1 2024, with a 5-year trough of $17.4 million in Q4 2021.
  • Its 5-year average for Total Liabilities is $46.8 million, with a median of $42.8 million in 2022.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Total Liabilities soared by 19169.87% in 2022, and later crashed by 8037.11% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Total Liabilities stood at $17.4 million in 2021, then skyrocketed by 191.7% to $50.8 million in 2022, then soared by 65.25% to $84.0 million in 2023, then plummeted by 65.64% to $28.9 million in 2024, then rose by 6.5% to $30.7 million in 2025.
  • Its Total Liabilities was $30.7 million in Q3 2025, compared to $26.7 million in Q2 2025 and $18.3 million in Q1 2025.